Add to a list

Inactive Instrument

Northwest Biotherapeutics, Inc. Stock Other OTC

NWBO

US66737P6007

Biotechnology & Medical Research

OTC Markets Traded

Valuation: Northwest Biotherapeutics, Inc.

Market Cap	273M 240M 224M 206M 385M 26.19B 395M 2.66B 1.04B 12.96B 1.03B 1B 44.81B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	370M 325M 303M 278M 521M 35.4B 534M 3.59B 1.41B 17.52B 1.39B 1.36B 60.55B	EV / Sales 2026 *	-	EV / Sales 2027 *	10.2x
Free-Float	95.04%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Latest news : Northwest Biotherapeutics, Inc.

07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
05-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
04-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
25-10-31	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
25-10-26	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
25-10-23	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
25-08-26	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI
25-08-18	Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman	CI
25-08-14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

More news

Press Releases: Northwest Biotherapeutics, Inc.

07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
07-02	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
05-15	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ
04-30	Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform	PR
04-21	Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic	PR

More press releases

Managers and Directors: Northwest Biotherapeutics, Inc.

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	2007-05-31
Linda Powers CEO	Chief Executive Officer	71	2011-06-07
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	1999-12-31

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	1997-12-31
Linda Powers CHM	Chairman	71	2007-05-16
Navid Malik BRD	Director/Board Member	57	2012-03-31

More insiders

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NORTHWEST BIOTHERAPEUTICS, INC.	-6.38%	-8.82%	-	-	273M
ARGENX SE	-2.11%	-4.39%	+45.64%	+66.74%	55.2B
WUXI APPTEC CO., LTD.	+2.83%	+0.48%	+28.18%	+82.59%	55.6B
BIONTECH SE	+0.54%	+1.22%	-16.62%	-13.47%	23.51B
INSMED INCORPORATED	-0.97%	-3.30%	-1.79%	+383.00%	22.35B
WUXI BIOLOGICS (CAYMAN) INC.	-4.01%	-3.67%	+13.17%	-14.29%	20.6B
GENMAB A/S	-1.04%	-2.60%	+26.72%	-33.46%	17.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.34%	-7.77%	+23.78%	+536.66%	15.16B
EXELIXIS, INC.	-2.09%	+0.64%	+49.78%	+178.74%	13.91B
PHARMAESSENTIA CORPORATION	-3.14%	-8.47%	+165.37%	+292.18%	13.74B
Average	-1.91%	-1.27%	+37.14%	+164.30%	26.39B
Weighted average by Cap.	-0.71%	-0.52%	+32.49%	+127.48%

	2026 *	2027 *
Net sales	-	38.93M 34.21M 31.93M 29.31M 54.86M 3.73B 56.21M 379M 148M 1.85B 146M 143M 6.38B
Net income	-	-
Net Debt	96.08M 84.42M 78.8M 72.32M 135M 9.2B 139M 934M 365M 4.55B 361M 353M 15.74B	125M 110M 102M 94.04M 176M 11.97B 180M 1.22B 475M 5.92B 469M 459M 20.47B

Northwest Biotherapeutics, Inc. Stock Other OTC

Stocks

NWBO

US66737P6007

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc.

Latest news : Northwest Biotherapeutics, Inc.

Press Releases: Northwest Biotherapeutics, Inc.

Quotes and Performance

Managers and Directors: Northwest Biotherapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile